POLB.F Stock Overview
Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Poolbeg Pharma PLC Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.11 |
52 Week High | UK£0.11 |
52 Week Low | UK£0.11 |
Beta | 2.26 |
1 Month Change | 2.80% |
3 Month Change | 2.80% |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 10.00% |
Recent News & Updates
Recent updates
Shareholder Returns
POLB.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0% | -3.2% | -3.5% |
1Y | n/a | 11.7% | 20.2% |
Return vs Industry: Insufficient data to determine how POLB.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how POLB.F performed against the US Market.
Price Volatility
POLB.F volatility | |
---|---|
POLB.F Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: POLB.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine POLB.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2021 | 12 | Jeremy Skillington | www.poolbegpharma.com |
Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program.
Poolbeg Pharma PLC Fundamentals Summary
POLB.F fundamental statistics | |
---|---|
Market cap | US$61.22m |
Earnings (TTM) | -US$6.08m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-10.1x
P/E RatioIs POLB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
POLB.F income statement (TTM) | |
---|---|
Revenue | UK£0 |
Cost of Revenue | UK£0 |
Gross Profit | UK£0 |
Other Expenses | UK£4.89m |
Earnings | -UK£4.89m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0098 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did POLB.F perform over the long term?
See historical performance and comparison